Camidge, D. R., Girard, N., Lu, S., Gadgeel, S. M., Cuppens, K., Lee, S., Horinouchi, H., Kim, T. M., Delmonte, A., Pons-Tostivint, E., Jotte, R. M., Aanur, N., Coburn, H., Jiang, Q., Jennaro, T. S., Navas, T., Li, Y., Goldman, J. W. (2025). Phase 1b/2 study evaluating telisotuzumab adizutecan (ABBV-400; Temab-A) in combination with budigalimab in patients (pts) with advanced non-squamous (NSQ) non-small cell lung cancer (NSCLC) with no prior treatment for advanced disease and no actionable genomic alterations.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps8655